Comparing Crisaborole 2% Ointment and Tacrolimus 0.1% Ointment Combined with Excimer Light Therapy for Treating Stable Facial Vitiligo in Children and Adults
Led by Cairo University · Updated on 2026-10-29
35
Participants Needed
1
Research Sites
2 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether crisaborole 2% ointment can effectively treat stable patches of facial vitiligo in children and adults of all genders. This study also compares the safety and tolerability of crisaborole 2% ointment with tacrolimus 0.1% ointment in similar patients. The goal is to determine if crisaborole works as well as tacrolimus for stable localized facial vitiligo.
Participants will be randomly assigned to one of two groups one applying crisaborole 2% ointment and the other applying tacrolimus 0.1% ointment. Both groups will apply their assigned ointment twice daily to the vitiligo patches on their face. In addition, all participants will undergo Excimer light therapy sessions twice a week for up to 6 months or until complete repigmentation occurs, whichever comes first.
During the study, participants will visit the clinic twice weekly for Excimer light treatments, checkups, and photography sessions. They will also keep a diary to track their symptoms. Researchers will measure changes in vitiligo using the Facial Vitiligo Area Scoring Index and the Vitiligo Extent Score for a Target Area at the start, 12 weeks, and 24 weeks. Secondary measures include time to repigmentation onset, impact of vitiligo on quality of life, and patient satisfaction. The trial is expected to continue until November 2026.
CONDITIONS
Brief Title
Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.
Research Team
R
Riham M Mohamed, MD, MSc., PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Localized facial vitiligo involving less than 50% of the face
Stable vitiligo with Vitiligo Disease Activity (VIDA) score of 0 or less
Vitiligo Signs of Activity Score (VSAS) equal to 0
Ability and willingness to follow treatment and attend visits
You will not qualify if you...
Younger than 6 years old
Segmental vitiligo
Vitiligo universalis
Pregnancy or breastfeeding
History of vitiligo transplantation procedure within past 6 months
Known allergy to study medications
History of any skin bleaching treatment for vitiligo or other skin conditions
Contraindications to Excimer light therapy such as skin cancer or photosensitivity disorders
Current use of systemic therapy or phototherapy
Use of topical treatments requiring a 2-week washout before and during study
UV light exposure requiring 8-week washout before and during study
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Treatment
Duration - Up to 6 months or until complete repigmentation
Participants apply either crisaborole 2% ointment or tacrolimus 0.1% ointment twice daily to facial vitiligo patches. They also attend Excimer light therapy sessions twice weekly.
Twice weekly visits
Follow-up
Duration - Up to 6 months from treatment start
Researchers monitor participants' vitiligo improvement through scoring assessments and patient diaries.
Regular assessments at 12 and 24 weeks
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating MH004 Ointment for Treating Non-segmental Vitiligo in Adolescents and Adults Ages 12 to 75
Phase 1 Study to Test Safety and Effectiveness of CGB-600 Gel for Treating Facial and Neck Vitiligo in Adults Aged 18 to 60
Global Real-World Study of Disease Impact in Adolescents and Adults with Moderate to Severe Alopecia Areata, Non-Segmental Vitiligo, or Hidradenitis Suppurativa
Study on Factors Affecting How Well Ruxolitinib Cream Works to Treat Vitiligo in Patients Aged 12 and Older
Randomized, Double-Blind Study Comparing EB06 Infusion to Placebo in Adults with Moderate to Severe Non-segmental Vitiligo
Study of LY4005130 Versus Placebo Administered Intravenously to Adults with Non-Segmental Vitiligo Evaluating Safety and Efficacy Over 24 Weeks
Safety and Exploratory Efficacy Study of TEV-53408 Injection for Adults With Vitiligo
Evaluating Vitiligo Spot Activity and Changes with Polarized Dermoscopy, Sub-Ultraviolet Reflectance, and Ultraviolet Fluorescence Imaging An Observational Study
Study of Autologous Non-cultured Epidermal Cell Suspension Transplantation to Treat Vitiligo in Patients Aged 8 to 65
Betamethasone Phonophoresis Treatment for Adults with Vitiligo Aged 25 to 40 Years
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter.